Considering the underlying diagnosis of the recipient, the most striking effects were found in KIR2DL3, where we detected obvious differences among myeloid and lymphoid neoplasms (in the second and third month after HSCT p < 0.05). The gene discussed is KIR2DL3; the disease is lymphoid neoplasm.